Create a Free Account
or
Create a Free Account
or
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and maintains $76 price target.
Stifel analyst Bradley Canino maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $90 to $99.
B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $80 to $76.
BMO Capital analyst Etzer Darout maintains Merus (NASDAQ:MRUS) with a Outperform and raises the price target from $84 to $91.
Truist Securities analyst Asthika Goonewardene maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $69...
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...
The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses a...
B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $61 to $80.
